Core Viewpoint - Silver诺医药-B (02591.HK) has received formal acceptance from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its clinical trial application of its core product, Isu-Paglutide α, for the treatment of diabetes in pets, with Phase I trials expected to commence in the first quarter of 2026 [1] Group 1: Product Development - The company believes that the development of diabetes medication for pets has significant potential due to increasing consumer willingness to invest in extending the lifespan of their pets [1] - The board views this research and development as aligned with the company's long-term business development strategy, laying a solid foundation for future entry into the pet pharmaceuticals market [1] Group 2: Regulatory Compliance and Trial Progress - The company has complied with all standards and regulatory requirements related to veterinary drug research and registration as mandated by the Ministry of Agriculture [1] - Successful completion of preclinical trials has shown positive progress in terms of efficacy and safety for Isu-Paglutide α in managing pet diabetes, providing a reasonable basis for subsequent clinical trials and registration applications [1]
银诺医药-B(02591.HK)：依苏帕格鲁肽α的新兽药临床试验申请获受理